Reflecting on the Scientific Achievements of Quotient Sciences in 2022

I chose to enter the pharmaceutical industry because I had a passion for science and a determination to have a positive impact on the world. It seemed that breakthroughs were being made almost every day that could lead to better treatments for diseases and conditions, and I wanted to be a part of that. Fast forward several decades, and I am privileged to work here at Quotient Sciences with some of the world’s best scientists innovating drug development to get new medicines to market faster. "Molecule to cure. Fast.^TM" has become our mantra, and the benefits of our unique, integrated Translational Pharmaceutics^® platform have been recognized across the industry and I know very much appreciated by our clients. Even so, it is very easy to lose sight of the tremendous impact we are having, particularly when we are busy, so as we approach the end of 2022, it is a great opportunity to look back at some of our key scientific achievements.

Together with our clients and collaborators, in 2022 Quotient Sciences’ scientists have published 10 papers in peer-reviewed journals, covering subjects as diverse as nanoparticle synthesis, clinical pharmacology, human ADME studies, and pediatric drug development. I think this is a tremendous reflection of the multidisciplinary environment we have here at Quotient Sciences, one that enables us to deliver truly integrated programs for our clients and accelerate their product development. Furthermore, with the world opening up after the pandemic, our scientists and thought leaders presented at numerous conferences around the globe, communicating to the wider scientific community some of the innovations and advancements we have been involved in. This resulted in 15 poster presentations, 15 seminars, and 13 podium presentations. Thank you to all of my colleagues and our collaborators for publishing their work and contributing to the global scientific community.

In addition, throughout the year we have continued to invest in our people and facilities so we can better serve the needs of our clients. In February, we announced the integration of drug substance into our Translational Pharmaceutics platform, uniting drug substance, drug product, and clinical testing activities all within one organization and led by a single program manager. In September, we completed major investments and expansions at our Nottingham, UK, and Reading, UK, facilities, with the new clinical pharmacology space and expanded development laboratories increasing our capacity to conduct integrated Translational Pharmaceutics programs for our clients. Furthermore, in October, we completed a major expansion of our drug substance manufacturing facility in Alnwick, UK, allowing us to support our clients into the later stages of development.

I am delighted that Quotient Sciences was recognized with multiple CRO Leadership Awards this year. The CRO Leadership Awards recognize top-performing outsourcing organizations in the drug development space. We received leadership awards in all five categories: Capabilities, Compatibility, Expertise, Reliability, and Quality. We were also honored with two champion awards in Expertise and Reliability. In addition, we were a finalist for Best CRO in the OBN Awards this year. The OBN Awards are designed to celebrate innovation and outstanding achievement across all corners of the life sciences industry.

These are of course only a small sample of our scientific achievements, and day in and day out one of my colleagues is making a breakthrough, sometimes small, sometimes larger, but each continues our relentless mission to get medicines to patients faster.

Details and links to the scientific papers and posters that we published in 2022 are provided below. Please contact us if you would like any further information on any of our publications or our drug development capabilities.

Kind regards,

Andy Lewis, Global Vice President of Integrated Pharmaceutical Sciences

Scientific papers

• "Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects: A Proof-of-Concept Study", published in The Journal of Clinical Psychopharmacology
  Access paper
   
• "Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects", published in Drug Metabolism and Disposition
  Access paper
   
• "Practical and operational considerations related to paediatric oral drug formulation: An industry survey ", published in The International Journal of Pharmaceutics
  Access paper
   
• "Controlled synthesis of SPION@SiO₂ nanoparticles using design of experiments", published in Materials Advances
  Access paper
   
• "Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial", published in EBioMedicine
  Access paper
   
• "Phase 1 Studies to Evaluate the Food Effect and Relative Bioavailability of Tablet and Capsule Formulations of Belumosudil in Healthy Adult Subjects", published in Clinical Pharmacology in Drug Development
  Access paper
   
• "A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors", published in Clinical Pharmacology in Drug Development
  Access paper
   
• "Absolute Bioavailability, Mass Balance, and Metabolic Profiling Assessment of [¹⁴C]-Belumosudil in Healthy Men: A Phase 1, Open-Label, 2-Part Study", published in Clinical Pharmacology in Drug Development
  Access paper
   
• "CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production", published in Arthritis Research & Therapy 
  Access paper
   
• "Absorption, metabolism and excretion of opicapone in human healthy volunteers", published in The British Journal of Clinical Pharmacology
  Access paper

Scientific posters

• "Safety, tolerability, and pharmacokinetics of the oligomer modulator anle138b: a first-in-human randomised, double-blind, placebo-controlled phase 1 trial", presented at the Advances in Science & Therapy International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) 2022
  Access poster
   
• "RANDOMISED OPEN-LABEL STUDY TO ASSESS RELATIVE BIOAVAILABILITY OF DIFFERENT ORAL FORMULATIONS, THE EFFECT OF FOOD ON ABSORPTION AND THE ABSOLUTE BIOAVAILABILITY OF AZD9833 (CAMIZESTRANT) IN POST-MENOPAUSAL HEALTHY FEMALE VOLUNTEERS", presented at the 123^rd Annual Meeting of the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2022
  Link to follow
   
• "Applications of Lipid-based Formulations and the Benefits of Integrating Manufacturing and Clinical Testing in Formulation Selection", presented at the 13^th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical (PBP) Technology 2022
  Access poster
   
• "The use of electrospraying as a means of drug loading into mesoporous silica particles for enhanced dissolution", presented at the 13^th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical (PBP) Technology 2022
  Access poster
   
• "Why Archiving is a Crucial Part of Any Clinical Trial", presented at the 38^th Society of Quality Assurance (SQA) Annual Meeting 2022
  Access poster
   
• "Preparation of Coamorphous Ciprofloxacin Formulations with Enhanced Deposition Parameters for Dry Powder Inhalation", presented at Respiratory Drug Delivery (RDD) 2022
  Link to follow
   
• "A Decade of Human ADME at Quotient Sciences: Reviewing Key Study Design Variables and Outcomes ", presented at the International Society for the Study of Xenobiotics (ISSX) 2022
  Access poster
   
• "Understanding the Absorption, Metabolism and Excretion of Masitinib in Healthy Male Subjects ", presented at the International Society for the Study of Xenobiotics (ISSX) 2022
  Access poster
   
• "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study to Assess Safety, Tolerability & Pharmacokinetics (PK) of Amilo-5MER in Healthy Volunteers", presented at the British Pharmacological Society, Pharmacology 2022
  Access poster
   
• "Development of a novel oral suspension formulation of a candidate API for administration to paediatric patients", presented at the 14^th Annual European Paediatric Formulation Initiative (EuPFI) Conference 2022
  Access poster
   
• "Formulation and Taste Assessments in First in Human Studies – Evolving beyond Safety, Tolerability and Pharmacokinetics", presented at the American Association of Pharmaceutical Scientists (AAPS) PharmSci360 2022
  Access poster
   
• "KILO SCALE SYNTHESIS IN DAISY CHAINED FLOW REACTORS", presented at the American Association of Pharmaceutical Scientists (AAPS) PharmSci360 2022
  Access poster
   
• "Benznidazole pharmacokinetics in adults and children: Application of PBPK modeling to explore the impact of age on benznidazole pharmacokinetics", presented at the 13^th American Conference on Pharmacometrics (ACoP) 2022
  Access poster
   
• "QUALIFICATION OF GASTROPLUS^® PBPK MODELLING SOFTWARE TO SUPPORT DECISION MAKING IN CLINICAL DEVELOPMENT", presented at Pharmacokinetics UK (PKUK) 2022
  Access poster
   
• "A Phase I Study of the Cancer-specific Vaccine FMPV-1 in Healthy Male Subjects to Assess Safety and Immune Response", presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2022
  Access poster